Expanding the potential of CXCR4 targeting beyond hematologic malignancies, recent studies have also explored the use of 212Pb/203Pb-labeled agents in CXCR4-expressing tumors, demonstrating therapeutic efficacy in murine models of small cell lung cancer [99]. This evidence concerns the gene CXCR4 and small cell lung carcinoma.